In the previous Biomed II program, a European concerted action of clinicians and pathologists has been established, to define the clinical characteristics as well as the precise morphological criteria for the sub classification of MCL. Based on this established European infrastructure, we are planning to extend our focus of research to the basic molecular risk factors in MCL. This research network is structured into 4 differentially focussed work packages, each of tem representing an international collaboration of several research groups:
(1) primary genetic alterations and markers of maturation
(2) Cell cycle deregulation in MCL
(3) Secondary alterations and sequential analysis in MCL
(4) Functional studies of MCL.
This approach will identify high-risk patients and finally direct the development of future innovative treatment options.
Funding SchemeCSC - Cost-sharing contracts
60054 Frankfurt Am-main
2311 EZ Leiden
E1 4NS London